U.S. markets close in 5 hours 45 minutes
  • S&P 500

    4,289.83
    -7.31 (-0.17%)
     
  • Dow 30

    33,999.63
    +87.19 (+0.26%)
     
  • Nasdaq

    13,039.22
    -88.83 (-0.68%)
     
  • Russell 2000

    2,011.89
    -9.46 (-0.47%)
     
  • Crude Oil

    89.87
    +0.46 (+0.51%)
     
  • Gold

    1,789.80
    -8.30 (-0.46%)
     
  • Silver

    20.06
    -0.21 (-1.05%)
     
  • EUR/USD

    1.0176
    +0.0011 (+0.11%)
     
  • 10-Yr Bond

    2.8680
    +0.0770 (+2.76%)
     
  • GBP/USD

    1.2086
    +0.0028 (+0.23%)
     
  • USD/JPY

    134.4340
    +1.1620 (+0.87%)
     
  • BTC-USD

    23,868.95
    -290.16 (-1.20%)
     
  • CMC Crypto 200

    568.02
    -3.89 (-0.68%)
     
  • FTSE 100

    7,549.26
    +40.11 (+0.53%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oxford Biomedica plc (OTC: OXBDFsigned a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine beyond 2022.

  • The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020.

  • The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the original commitment, is expected to complete in the last quarter of 2022.

  • Under the expanded deal, AstraZeneca will have access to Oxford Biomedica's Oxbox manufacturing facility to produce its shot on an as-needed basis beyond 2022.

  • Oxford Biomedica expects to recognize aggregate revenues of approximately £30 million from AstraZeneca in the current financial year.

  • "I am delighted that our close partnership with AstraZeneca has been extended. I am proud of the work of all our colleagues at Oxford Biomedica that has enabled us to deliver more than 100 million doses of lifesaving COVID-19 vaccine," Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented.

  • Price Action: AZN shares are down 1.89% at $64.82 during the premarket session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.